Amy Desrochers DiVasta
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Amy Desrochers DiVasta has a total of 82 co-authors. Here are the top co-authors by number of shared publications:
Catherine M. Gordon
Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, Maryland
13 shared publicationsHenry A. Feldman
Institutional Centers for Clinical and Translational Research, Boston Children's Hospital, Boston, Massachusetts; Division of Endocrinology, Boston Children's Hospital, Boston, Massachusetts
11 shared publicationsMarc R. Laufer
Boston Center for Endometriosis, Boston, Massachusetts
5 shared publicationsMark D. Hornstein
Boston Center for Endometriosis, Boston, Massachusetts
4 shared publicationsAllison F. Vitonis
Boston Center for Endometriosis, Boston Children's Hospital and Brigham and Women's Hospital, Boston, Massachusetts; Department of Obstetrics, Gynecology, and Reproductive Biology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts
3 shared publicationsC. M. Gordon
Division of Adolescent and Transition Medicine, Cincinnati Children’s Hospital Medical Center and University of Cincinnati College of Medicine, Cincinnati, USA
3 shared publications
Latest Publications
- Open Access
- 1 October 2024
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 7 (10) , e2441779
Low-Magnitude Mechanical Signals to Preserve Skeletal Health in Female Adolescents With Anorexia Nervosa
Importance: Malnourished adolescents and young adults with anorexia nervosa (AN) are at high risk for skeletal deficits.Objective: To examine whether low-magnitude mechanical signals (LMMS) could preserve bone mineral density (BMD) throughout 6 months in adolescents and young adults with AN.Design, Setting, and Participants: This double-blind, sham-controlled randomized clinical trial, conducted in a hospital-based specialty clinic, assessed female adolescents and young women without medical comorbidity or medication use that would compromise bone health. A total of 837 female adolescents were screened from January 1, 2012, to December 31, 2019, of whom 317 met the study criteria. Data analysis was performed from 2020 to 2024.Intervention: Platform delivering low-magnitude mechanical signals (LMMS) (0.3 g at 32-37 Hz) or sham (ie, placebo) signals for 10 minutes daily for 6 months.Main Outcomes and Measures: The primary outcome was trabecular volumetric BMD (vBMD) as measured by peripheral quantitative computed tomography of the tibia at baseline and 6 months. Secondary outcomes included cortical vBMD, cross-sectional area (CSA), areal BMD and body composition measured by dual-energy x-ray absorptiometry, and serum bone turnover markers.Results: Forty female adolescents and young women (median [IQR] age, 16.3 [15.1-17.6] years; median [IQR] percentage median BMI for age, 87.2% [81.0%-91.6%]) completed the trial. Total bone vBMD changes were nonsignificant in both groups (95% CI for difference in median change between groups, −57.11 to 2.49): in the LMMS group, vBMD decreased from a median (IQR) of 313.4 (292.9-344.6) to 309.4 (290.4-334.0) mg/cm3, and in the placebo group, it increased from a median (IQR) of 308.5 (276.7-348.0) to 319.2 (309.9-338.4) mg/cm3. Total CSA at the 4% tibia site increased from a median (IQR) of 795.8 (695.0-844.8) mm2 to 827.5 (803.0-839.4) mm2 in the LMMS group, whereas in the placebo group, it decreased from 847.3 (770.5-915.3) mm2 to 843.3 (828.9-857.7) mm2 (95% CI for difference in median change between groups, 2.94-162.53). Median (IQR) trabecular CSA at the 4% tibia site increased from 616.3 (534.8-672.3) mm2 to 649.2 (638.0-661.4) mm2 in the LMMS group but decreased in the placebo group from 686.4 (589.0-740.0) mm2 to 647.9 (637.3-661.9) mm2 (95% CI for difference in median change between groups, 2.80-139.68 mm2). Changes in cortical vBMD, cortical section modulus, and muscle CSA were not significant between groups. The 6-month changes in trabecular and total bone CSA at the tibia 4% site (weight-bearing trabecular bone) were significantly different between groups (these measures increased in the LMMS group but decreased in the placebo group; total bone CSA: 95% CI, 2.94-162.53; P = .01; trabecular CSA: 95% CI, 2.80-139.68; P = .02). Greater increases in body mass index were seen in the placebo group (median [IQR] gain, 0.5 [–0.3 to +2.1]) than in the LMMS group (median [IQR] gain, +0.4 [–0.3 to +2.1]), perhaps due to differences in fat mass accrual. No adverse events occurred related to the LMMS intervention.Conclusions and Relevance: In this randomized clinical trial of female adolescents and young women with AN, a 6-month LMMS intervention did not yield improvement in tibial trabecular vBMD. However, LMMS led to increases in total and trabecular CSA at the tibia. These results suggest an early positive response of increased bone turnover and trabecular bone quantity due to the LMMS intervention. Future studies should use a longer duration of intervention, consider strategies to optimize adherence, and potentially focus on a more profoundly malnourished patient population.Trial Registration: ClinicalTrials.gov Identifier: NCT01100567
- 1 October 2024
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 7 (10) , e2441779
Open AccessLow-Magnitude Mechanical Signals to Preserve Skeletal Health in Female Adolescents With Anorexia Nervosa
Importance: Malnourished adolescents and young adults with anorexia nervosa (AN) are at high risk for skeletal deficits.Objective: To examine whether low-magnitude mechanical signals (LMMS) could preserve bone mineral density (BMD) throughout 6 months in adolescents and young adults with AN.Design, Setting, and Participants: This double-blind, sham-controlled randomized clinical trial, conducted in a hospital-based specialty clinic, assessed female adolescents and young women without medical comorbidity or medication use that would compromise bone health. A total of 837 female adolescents were screened from January 1, 2012, to December 31, 2019, of whom 317 met the study criteria. Data analysis was performed from 2020 to 2024.Intervention: Platform delivering low-magnitude mechanical signals (LMMS) (0.3 g at 32-37 Hz) or sham (ie, placebo) signals for 10 minutes daily for 6 months.Main Outcomes and Measures: The primary outcome was trabecular volumetric BMD (vBMD) as measured by peripheral quantitative computed tomography of the tibia at baseline and 6 months. Secondary outcomes included cortical vBMD, cross-sectional area (CSA), areal BMD and body composition measured by dual-energy x-ray absorptiometry, and serum bone turnover markers.Results: Forty female adolescents and young women (median [IQR] age, 16.3 [15.1-17.6] years; median [IQR] percentage median BMI for age, 87.2% [81.0%-91.6%]) completed the trial. Total bone vBMD changes were nonsignificant in both groups (95% CI for difference in median change between groups, −57.11 to 2.49): in the LMMS group, vBMD decreased from a median (IQR) of 313.4 (292.9-344.6) to 309.4 (290.4-334.0) mg/cm3, and in the placebo group, it increased from a median (IQR) of 308.5 (276.7-348.0) to 319.2 (309.9-338.4) mg/cm3. Total CSA at the 4% tibia site increased from a median (IQR) of 795.8 (695.0-844.8) mm2 to 827.5 (803.0-839.4) mm2 in the LMMS group, whereas in the placebo group, it decreased from 847.3 (770.5-915.3) mm2 to 843.3 (828.9-857.7) mm2 (95% CI for difference in median change between groups, 2.94-162.53). Median (IQR) trabecular CSA at the 4% tibia site increased from 616.3 (534.8-672.3) mm2 to 649.2 (638.0-661.4) mm2 in the LMMS group but decreased in the placebo group from 686.4 (589.0-740.0) mm2 to 647.9 (637.3-661.9) mm2 (95% CI for difference in median change between groups, 2.80-139.68 mm2). Changes in cortical vBMD, cortical section modulus, and muscle CSA were not significant between groups. The 6-month changes in trabecular and total bone CSA at the tibia 4% site (weight-bearing trabecular bone) were significantly different between groups (these measures increased in the LMMS group but decreased in the placebo group; total bone CSA: 95% CI, 2.94-162.53; P = .01; trabecular CSA: 95% CI, 2.80-139.68; P = .02). Greater increases in body mass index were seen in the placebo group (median [IQR] gain, 0.5 [–0.3 to +2.1]) than in the LMMS group (median [IQR] gain, +0.4 [–0.3 to +2.1]), perhaps due to differences in fat mass accrual. No adverse events occurred related to the LMMS intervention.Conclusions and Relevance: In this randomized clinical trial of female adolescents and young women with AN, a 6-month LMMS intervention did not yield improvement in tibial trabecular vBMD. However, LMMS led to increases in total and trabecular CSA at the tibia. These results suggest an early positive response of increased bone turnover and trabecular bone quantity due to the LMMS intervention. Future studies should use a longer duration of intervention, consider strategies to optimize adherence, and potentially focus on a more profoundly malnourished patient population.Trial Registration: ClinicalTrials.gov Identifier: NCT01100567
- 23 May 2024
- Published by Springer Nature
- p. 85-106
Sexual and Reproductive Health
- Open Access
- 24 July 2021
- Published by Elsevier in F&S Reports
- Vol. 2 (4) , 454-461
Nonhormonal therapy for endometriosis: a randomized, placebo-controlled, pilot study of cabergoline versus norethindrone acetate
- 24 July 2021
- Published by Elsevier in F&S Reports
- Vol. 2 (4) , 454-461
Open AccessNonhormonal therapy for endometriosis: a randomized, placebo-controlled, pilot study of cabergoline versus norethindrone acetate
- 1 October 2020
- Published by Elsevier in Journal of Adolescent Health
- Vol. 67 (4) , 557-561
Quality of Life in Adolescent and Young Adult Women With Dyspareunia and Endometriosis
- 1 October 2020
- Published by Elsevier in Journal of Adolescent Health
- Vol. 67 (4) , 557-561
Quality of Life in Adolescent and Young Adult Women With Dyspareunia and Endometriosis
- 1 December 2019
- Published by Elsevier in Journal of Pediatric and Adolescent Gynecology
- Vol. 32 (6) , 615-621
Will it Hurt? The Intrauterine Device Insertion Experience and Long-Term Acceptability Among Adolescents and Young Women
- 1 December 2019
- Published by Elsevier in Journal of Pediatric and Adolescent Gynecology
- Vol. 32 (6) , 615-621
Will it Hurt? The Intrauterine Device Insertion Experience and Long-Term Acceptability Among Adolescents and Young Women
- 1 October 2019
- Published by Elsevier in Journal of Adolescent Health
- Vol. 65 (4) , 462-468
Impact of Adrenal Hormone Supplementation on Bone Geometry in Growing Teens With Anorexia Nervosa
- 1 October 2019
- Published by Elsevier in Journal of Adolescent Health
- Vol. 65 (4) , 462-468
Impact of Adrenal Hormone Supplementation on Bone Geometry in Growing Teens With Anorexia Nervosa
- 1 April 2018
- Published by Elsevier in Fertility and Sterility
- Vol. 109 (4) , 685-690
Prevalence of migraines in adolescents with endometriosis
- 1 April 2018
- Published by Elsevier in Fertility and Sterility
- Vol. 109 (4) , 685-690
Prevalence of migraines in adolescents with endometriosis
- Top Cited Papers
- 1 March 2018
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 218 (3) , 324.e1-324.e11
Spectrum of symptoms in women diagnosed with endometriosis during adolescence vs adulthood
- 1 March 2018
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 218 (3) , 324.e1-324.e11
Top Cited PapersSpectrum of symptoms in women diagnosed with endometriosis during adolescence vs adulthood
- 1 February 2017
- Published by Elsevier in Journal of Adolescent Health
- Vol. 60 (2) , 229-232
Effect of Exercise and Antidepressants on Skeletal Outcomes in Adolescent Girls With Anorexia Nervosa
- 1 February 2017
- Published by Elsevier in Journal of Adolescent Health
- Vol. 60 (2) , 229-232
Effect of Exercise and Antidepressants on Skeletal Outcomes in Adolescent Girls With Anorexia Nervosa